PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
PERRIGO Co plc
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$16.09−0.54 (-3.25%)
Close on Oct 19, 2026
- Market cap
- $2.25B
- P/E (TTM)
- –
- Dividend yield
- 7.21%
PERRIGO Co plc revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Self Care | $576.60M | $543.30M | – | – | $598.60M | $614.30M | – | – | – | – | – | – | 56.4% | -3.7% |
| Specialty Care | $226.60M | $207.00M | – | – | $233.10M | $199.10M | – | – | – | – | – | – | 22.2% | -2.8% |
| Infant Formula | $100.90M | $89.70M | – | – | $82.00M | $87.80M | – | – | – | – | – | – | 9.9% | +23.0% |
| CSCA | – | – | $697.00M | $645.60M | $622.00M | $620.70M | $744.20M | $671.30M | $634.10M | $644.10M | $744.40M | $703.50M | – | – |
| CSCI | – | – | $412.60M | $397.70M | $434.30M | $423.10M | $394.10M | $416.30M | $431.30M | $437.90M | $412.60M | $420.30M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Self Care | $78.70M | $68.50M | – | – | $93.90M | $112.80M | – | – | – | – | – | – | -16.2% |
| Specialty Care | $47.80M | $55.30M | – | – | $66.30M | $42.10M | – | – | – | – | – | – | -27.9% |
| Infant Formula | $4.00M | -$7.40M | – | – | -$12.20M | $10.60M | – | – | – | – | – | – | -132.8% |
| CSCA | – | – | -$872.70M | $94.70M | $45.10M | $64.00M | $82.80M | $102.20M | $69.30M | $15.70M | $117.60M | $91.10M | – |
| CSCI | – | – | -$365.00M | $37.40M | $59.20M | $39.60M | $39.90M | $48.90M | -$10.30M | $26.50M | -$78.80M | $13.60M | – |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $626.40M | $554.40M | $684.60M | $635.30M | $610.90M | $609.30M | $732.20M | $656.90M | $627.80M | $632.30M | $740.50M | $690.30M | 61.2% | +2.5% |
| Europe | $371.70M | $391.40M | $398.40M | $384.00M | $421.70M | $412.30M | $379.10M | $397.30M | $408.40M | $419.70M | $389.90M | $399.80M | 36.3% | -11.9% |
| All other countries | $24.70M | $23.40M | $26.60M | $24.00M | $23.70M | $22.30M | $27.00M | $33.30M | $29.30M | $30.10M | $26.50M | $33.70M | 2.4% | +4.2% |
| Ireland | $7.70M | $4.10M | $12.70M | $8.60M | $9.80M | $11.00M | $12.80M | $11.10M | $11.40M | $4.30M | $9.80M | $11.90M | 0.8% | -21.4% |
From the segment and revenue-disaggregation notes of Perrigo's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.